Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Mourad, Farouk"'
Publikováno v:
Egyptian Journal of Surgery. Oct-Dec2023, Vol. 42 Issue 4, p1131-1139. 9p.
Publikováno v:
Egyptian Journal of Surgery. Jan-Mar2021, Vol. 40 Issue 1, p290-299. 10p.
Publikováno v:
Egyptian Journal of Surgery. Apr-Jun2020, Vol. 39 Issue 2, p338-343. 6p.
Autor:
Burkhard Pieper, Mourad Farouk Rezk
Publikováno v:
Advances in Therapy
Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a significant disease burden on millions of patients while adding a major financial burden to societies and healthcare systems. The introduction of biologic medicines ha
Autor:
Juyoung Hong, Jae-Woong Hwang, Pia Høier, Shinjung Lee, Hyoung Taek Lim, Bjørn Fehrmann, Jinhan Chung, Mourad Farouk Rezk, Niels Hvorslev, Mette Ottosen, Hans C. Ebbers
Publikováno v:
Biodrugs
Background Biosimilars must meet stringent regulatory requirements, both at the time of authorization and during their lifecycle. Yet it has been suggested that divergence in quality attributes over time may lead to clinically meaningful differences
Autor:
Mourad Farouk Rezk, Burkhard Pieper, Janet Addison, Amine Issa, Hans C. Ebbers, Ulrich Freudensprung
Publikováno v:
Rheumatology and Therapy
Rheumatology and Therapy, Vol 6, Iss 3, Pp 317-338 (2019)
Rheumatology and Therapy, Vol 6, Iss 3, Pp 317-338 (2019)
Introduction In 2016, SB4 (Benepali®) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice. Methods
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carlo Selmi, Klaus Krüger, Alain Cantagrel, Miguel Angel Abad Hernández, Ulrich Freudensprung, Mourad Farouk Rezk, Janet Addison
Publikováno v:
Clinical and experimental rheumatology. 39(2)
The objective of this non-interventional study was to evaluate the effectiveness and safety of the etanercept biosimilar SB4 (BenepaliTM) following transition from reference etanercept in patients with rheumatoid arthritis (RA) or axial spondyloarthr
Autor:
Janet Addison, Abad Hernández, Mourad Farouk Rezk, Klaus Krueger, Carlo Selmi, Ulrich Freudensprung, Alain Cantagrel
Publikováno v:
Poster Presentations.
Background: Having demonstrated bioequivalence and similar efficacy, safety and immunogenicity as the originator, SB4 is approved in the EU as an ETN biosimilar. There is limited evidence on outcomes of transition from originator to biosimilar in a m
Autor:
Krüger, Klaus, Zinke, Silke, Karberg, Kirsten, Freudensprung, Ulrich, Rezk, Mourad Farouk, Addison, Janet
Publikováno v:
46. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 32. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20180919-20180922; Mannheim; DOCEV.27 /20190205/
Background: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical Phase I and III studies that demonstrated similar efficacy, bioequivalence, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa7c8518278a65cf3755389cddb014a8
http://nbn-resolving.de/urn:nbn:de:0183-18dgrh0776
http://nbn-resolving.de/urn:nbn:de:0183-18dgrh0776